Androcur Indications/Uses

Women: Moderately severe to severe signs of androgenization: moderately severe/severe forms of hirsutism; moderately severe/severe androgen-dependent loss of scalp hair (moderately severe/severe androgenic alopecia); moderately severe/severe forms of acne and/or seborrhea associated with other features of androgenization.
For moderately severe to severe signs of androgenization in women, cyproterone acetate 50 mg is indicated when no satisfactory results have been achieved with lower dose cyproterone-containing products or with other treatment options.
Cyproterone acetate inhibits the influence of male sex hormones which are also produced by the female. It is thus possible to treat diseases in women caused either by increased production of androgens or a particular sensitivity to these hormones. Hirsutism and alopecia may be expected to recur over a period of time after cessation of treatment.
If Androcur is taken during pregnancy, the properties of the preparation may lead to signs of feminisation in the male foetus. Therefore, in women of childbearing potential, pregnancy must be excluded at the commencement of treatment and ethinyloestradiol taken as well to ensure contraception. This also promotes regular menstruation.
Men: Reduction of drive in sexual deviations: For reduction of drive in sexual deviations in men, cyproterone acetate 50 mg can be used when other interventions are considered inappropriate.
Androcur reduces the force of the sexual urge in men with sexual deviations. Whilst under treatment the man can control himself better in a predisposing stimulatory situation, but there is no influence on any deviating direction of sexual drive. Abnormal patterns of sexual behaviour require treatment when they are distressing to the patient. A pre-requisite for therapy is the desire by the patient for treatment.
Androcur therapy should be supplemented by psychotherapeutic and sociotherapeutic measures in order to exploit the period of reduced drive for personal and social re-orientation.
Inoperable prostatic carcinoma: To suppress "flare" with initial LHRH analogue therapy; in long term palliative treatment where LHRH analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred; in the treatment of hot flushes in patients treated with LHRH analogues or who have had orchidectomy.